Rofloxin 500mg Tablets

• 

Indications :-

Adults :

Uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens:

• Infections of the lower respiratory tract.
• In the treatment of outpatients with pneumonia due to Pneumococcus, ciprofloxacin should not be used as a drug of first choice. Ciprofloxacin can be regarded as a suitable treatment for pneumonias caused by Klebsiella, Enterobacter, Proteus, E. coli, Pseudomonas, Haemophilus, Branhamella, Legionella, and Staphylococcus.
• Infections of the kidneys and/or the efferent urinary tract.
• Infections of the genital organs, including adnexitis, gonorrhoea, prostatitis.
• Infections of the abdominal cavity (e.g. infections of the gastrointestinal tract or of the biliary tract, peritonitis).
• Infections of the skin and soft tissue.
• Infections of the bones and joints.
• Sepsis.
• Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication.

According to in-vitro investigations, the following pathogens can be regarded as sensitive:

E. coli, Shigella, Salmonella, Citrobacter, Klebsiella, Enterobacter, Serratia, Hafnia, Edwardsiella, Proteus (indole-positive and indole-negative), Providencia, Morganella, Yersinia; Vibrio, Aeromonas, Plesiomonas, Pasteurella, Haemophilus, Campylobacter, Pseudomonas, Legionella, Neisseria, Moraxella, Acinetobacter, Brucella; Staphylococcus, Listeria, Corynebacterium, Chlamydia.

The following show varying degrees of sensitivity:

Gardnerella, Flavobacterium, Alcaligenes, Streptococcus agalactiae, Enterococcus faecalis, Streptococcus pyogenes, Streptococcus pneumoniae, Viridans group Streptococci, Mycoplasma hominis, Mycobacterium tuberculosis, and Mycobacterium fortuitum.

The following are usually resistant:

 

• Enterococcus faecium, Ureaplasma urealyticum, Nocardia asteroides.
• With a few exceptions anaerobes are moderately sensitive e.g. Peptococcus, Peptostreptococcus to resistant e.g. Bacteroides.
• Ciprofloxacin has been shown to be active against Bacillus anthracis both in vitro and by use of serum levels as a surrogate marker.
• Ciprofloxacin is ineffective against Treponema pallidum.

·         
Children :

Cystic fibrosis
For the treatment of acute pulmonary exacerbation of cystic fibrosis associated with P. aeruginosa infection in paediatric patients aged 5-17 years.

Inhalational anthrax (post-exposure)
For the indication of inhalational anthrax (post-exposure

Complicated urinary tract infections and pyelonephritis
For complicated urinary tract infections or pyelonephritis due to E.coli in paediatric patients aged 1-17 years. 

The risk-benefit assessment indicates that administration of ciprofloxacin to paediatric patients is appropriate. Treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints/surrounding tissues. The use of ciprofloxacin for other indications is not recommended in children.